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Patients' understanding of chronic anticoagulant therapy: evaluation
of the knowledge of patients admitted in a cardiology unit
Darcy Vandenberghe, Marie Viala, David Belardi, Florence Leclercq,
Delphine Delseny, Richard Gervasoni, Macia Jean Christophe, Benoit
Lattuca, Francois Roubille
CHU ADV, Cardiologie, Montpellier, France
Purpose: There is good evidence that adherence to medical treatment is
enhanced by knowledge and understanding of the drug, its benefits and its
side-effects.
Objectives: To investigate knowledge and perceptions of antithrombotic
therapy among a population of patients receiving chronic anticoagulation
therapy with vitamine k antagonists (VKA) or direct oral anticoagulants
(DOA). 
Methods: We conducted a prospective study among 122 patients admitted
in our cardiology unit and receiving anticoagulant therapy for more than
3 months. Atrial fibrillation was the main indication of therapy (n=63, 51.6%)
and VKA concerned 87% of patients. All patients were invited to fill in a
questionnaire (11 questions), which was handed out by a nurse in a face-to-
face interview. None of the patients refused to fill in the questionnaire, which
was completed at once and independently. 
Results: While the vast majority of patients know that they have anti-
coagulant therapy (96,7%), patients presented a clear lack of knowledge
concerning mainly food and drug interaction (table 1), the possible conse-
quences of under- or over-anticoagulation (n=31; 25,4%), the reason why they
have this therapy (n=39; 32,7%) and how to control their treatment.
Comparing the two therapies, we observed a non significant difference in
knowledge concerning VKA and DOA except knowledge of risks of therapy
which was superior in the DOA group (p<0.05). 
In conclusion: Patients’ anticoagulant therapy knowledge, either vitamin
K antagonists or DOA, is poor. With the increasing use of DOA, from which
we have no more biologic control to assess compliance, improved patient edu-
cation and physician involvement in therapeutic education, is crucial. 
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Anxiety and depressive symptoms after acute coronary syndrome:
prevalence, evolution and predictive factors
Leila Simoné
Hôpital Robert Debré, Reims, France
Anxiety and depressive symptoms after acute coronary syndrome (ACS)
are associated with increased mortality and morbidity, more random cardiac
rehabilitation, unhealthy behaviours. The aim of this study was to determine
prevalence of these symptoms after ACS, and associated factors.
During 6 months, all patients admitted to the Hospital of Reims for ACS
were included. Hospital Anxiety and Depression Score (HADS) was used to
screen anxiodepressive symptoms during initial hospitalization and 3 months
later. The analysis focused on socio-demographic, clinico-biological and ther-
apeutic data. 
We included 101 patients. 40,6% had anxiety and depressive symptoms on
admission and 41,6% at 3 months. Factors associated with a high persistent
3 month score were: initial HADS score (r = 0,81 p<0.001), history of depres-
sion (OR 14,1; CI95% 1,7-42,4 p<0,001), history of coronary heart disease
(OR 5,8; 95% CI95% 1,7-19,6 p<0,001), young age (54,4 years ± 10,9
p 0,039), social isolation (OR 12,5; CI95% 4,2-37,3 p< ,001), smoking (OR
8,7; CI95% 3,5-21,7 p<0.001), physical inactivity (OR 5,1; CI95% 2, 3-10,9
p <0.001), early ventricular arrhythmias (OR 13,5; CI95% 5,1-35,9 p<0,001).
Also high C-reactive protein (OR 11,8; p< 0,001), a low HDL-cholesterol
(mean 0,4g/L p < 0.001), and high level of liver enzyme (OR 0,3; p<0,001)
were associated with positive score. 17 patients have attempted suicide and
2 patients have committed suicide. 
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